Belite Bio, Inc. Chief Executive Officer and Director Lin Yu-Hsin filed a statement of changes in beneficial ownership on October 30, 2026, reporting the vesting of 5,000 ordinary shares under a restricted stock unit award originally granted on September 15, 2025.

Key Highlights

  • Reporting person: Lin Yu-Hsin, serving as both Chief Executive Officer and Director of Belite Bio, Inc.
  • Transaction date: October 29, 2026, with the filing submitted October 30, 2026.
  • Shares acquired: 5,000 ordinary shares acquired at a price of $0, via transaction code J, reflecting RSU vesting.
  • RSU grant date: The underlying restricted stock units were originally granted on September 15, 2025, subject to performance criteria.
  • Vesting trigger: According to the filing, certain performance criteria were met on October 29, 2026, resulting in vesting of the RSUs as to 5,000 ordinary shares.
  • Beneficial ownership following transaction: Lin Yu-Hsin directly holds 187,949 ordinary shares following this transaction.

Performance-Based RSU Vesting by Belite Bio's CEO Lin Yu-Hsin

According to the filing, Lin Yu-Hsin, who serves as both Chief Executive Officer and Director of Belite Bio, Inc. (NASDAQ:BLTE), reported the acquisition of 5,000 ordinary shares on October 29, 2026. The shares were received through the vesting of restricted stock units originally granted on September 15, 2025. The transaction was recorded under code J and carried a price of $0, consistent with an RSU award settlement rather than an open-market purchase.

The filing states that the RSU award was structured to vest "upon satisfaction of several performance criteria." According to the explanation of responses included in the filing, certain of those performance criteria were met on October 29, 2026, triggering the vesting event for 5,000 of the underlying ordinary shares. Belite Bio is a clinical-stage biopharmaceutical company, and equity awards tied to performance milestones are a common component of executive compensation in this sector. Following the reported transaction, Lin Yu-Hsin is disclosed as directly and beneficially owning 187,949 ordinary shares in total.

The filing was made by one reporting person and is not identified as an amendment to a prior filing. No derivative securities transactions were reported in Table II of the filing. The ownership form for the reported shares is listed as direct.

What Was Disclosed

Belite Bio CEO and Director Lin Yu-Hsin disclosed the vesting of 5,000 ordinary shares on October 29, 2026, under a performance-based RSU grant originally awarded on September 15, 2025, bringing total direct beneficial ownership to 187,949 ordinary shares.